Results 1 to 10 of about 1,313,485 (188)

Guselkumab binding to CD64⁺ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling. [PDF]

Front Immunol
IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue. Our complementary analyses of transcriptomic datasets from psoriasis and IBD showed increased expression of ...
Sachen KL, Hammaker D, Sarabia I, Stoveken B, Hartman J, Leppard KL, Manieri NA, Bao P, Greving C, Lacy ER, DuPrie M, Wertheimer J, Deming JD, Brown J, Hart A, Li HH, Freeman TC, Keyes B, Kohler K, White I, Karpowich N, Steele R, Elloso MM, Fakharzadeh S, Goyal K, Lavie F, Abreu MT, Allez M, Atreya R, Bissonnette R, Eyerich K, Krueger JG, McGonagle D, McInnes IB, Ritchlin C, Fourie AM.   +35 more
europepmc   +5 more sources

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. [PDF]

Front Immunol
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases ...
Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, Fourie A, Fakharzadeh S, Sherlock JP, Yang YW, Cua DJ, McInnes IB.   +11 more
europepmc   +6 more sources

Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials [PDF]

Frontiers in Immunology
BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease that impacts both the skin and joints. Currently, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors have become integral components of PsA treatment regimens.
Shan Gao, Xingxing Xie, Ling Fan, Linyuan Yu   +3 more
doaj   +2 more sources

Clinical benefits and complication profile of IL-23 inhibitors in patients with psoriatic arthritis: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Zeng J, Lin L, Li W, Gao X, Li Q, Zhou X, Liu W, Zhong X, Yang Y, Zhang X, Luo Q.   +10 more
europepmc   +3 more sources

The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis [PDF]

Musculoskeletal Care, 2022
AbstractBackgroundPsoriatic arthritis (PsA) is a chronic inflammatory arthritis characterised by musculoskeletal and extra‐articular manifestations, most notably psoriasis. While the underlying pathogenetic mechanisms are not yet fully understood, a central role has been identified for the IL‐23/IL‐17 pathway.ObjectivesWe briefly describe the role of ...
Fragoulis, George E., Siebert, Stefan
openaire   +3 more sources

Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization. [PDF]

J Clin Med
Pedicelli A, Bessissow T, Afif W.
europepmc   +3 more sources

The regulatory mechanism and potential application of IL-23 in autoimmune diseases

Frontiers in Pharmacology, 2022
IL-23 is a heterodimeric pro-inflammatory cytokine secreted by dendritic cells and macrophages that belongs to the IL-12 family. It has pro-inflammatory effects and is a key cytokine and upstream regulatory cytokine involved in protective immune ...
De-Kai Xiong, Xiang Shi, Miao-Miao Han, Xing-Min Zhang, Na-Na Wu, Xiu-Yue Sheng, Ji-Nian Wang, Ji-Nian Wang   +7 more
doaj   +1 more source

Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview

Frontiers in Immunology, 2021
Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19) and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12).
Claudia Schinocca, Chiara Rizzo, Serena Fasano, Giulia Grasso, Lidia La Barbera, Francesco Ciccia, Giuliana Guggino   +6 more
doaj   +1 more source

Bullous pemphigoid induced by anti-IL-23 monoclonal antibody in a psoriatic patient: a case report. [PDF]

Front Med (Lausanne)
Xi R, Cao Y, Zhuang Q, Ma L, Tao M, Li Y.   +5 more
europepmc   +3 more sources

Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis. [PDF]

Life (Basel)
Annunziata G, Scala E, Mercurio L, Sanna L, Dattolo A, Pagnanelli G, Lolli MG, Belli R, Moretta G, Savastano S, Muscogiuri G, Maisto M, Ciampaglia R, Piccolo V, Tenore GC, Albanesi C, Madonna S, Barrea L.   +17 more
europepmc   +3 more sources